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Dear Editor,
A 63-year-old patient presented with abdominal pain. A
computerized tomogram scan showed a gallbladder mass
(Fig. 1a). A positron emission tomogram revealed addi-
tional FDG-avid lesions in the sternum, ribs, bilateral
humeri, vertebral column, and pelvic bone (Fig. 1b).
Magnetic resonance imaging confirmed vertebral lytic
lesions (Fig. 1c). A serum protein electrophoresis showed
a monoclonal band (IgA l 16.2g/l), and he was referred
for suspected plasma cell myeloma (PCM). A bone mar-
row biopsy, however, showed 19 % infiltration by mono-
clonal B cells, expressing CD20, but negative for CD3−,
CD5, CD10, CD138, IgA, IgG, and IgM (Fig. 1d). These
cells showed κ−light chain restriction (Fig. 1e, f). Stain-
ing with CD138 highlighted less than 1 % plasma cells,
while the lymphoma cells do not express CD138. In
view of the discrepancy, cholecystectomy was performed
showing a plasmacytoma (Fig. 1g). The plasma cells
were CD138 positive, CD20 negative, and also positive
for cytoplasmic lambda chain and IgA, but negative for
IgG, IgM, and κ−light chain restriction. (Fig. 1h, i).
They also expressed CD56 and cyclin D1. The double
pathology was treated with R-CEOP ×6 (rituximab, cy-
clophosphamide, epirubicin, vincristine, and predniso-
lone) together with maintenance with thalidomide and
bortezomib (weekly×16 doses) and radiotherapy to both
humerus. A complete remission by radiological and se-
rum immunofixation assessment was shown at 1 year. He
refused an autologous stem cell transplantation (SCT).
The clonal relationship between the two lesions was
investigated by polymerase chain reaction using IgH VJ
primers followed by cloning and sequencing, using DNA
from the homogeneous plasmacytoma and microdissected
lymphoma cells from the trephine biopsy [1]. This showed a
direct relationship between the two B cell clones in terms of
band size and sequence homology (Fig. 1j and k).
This case is interesting in terms of pathogenesis and treat-
ment. In terms of pathogenesis, cases of concomitant B cell
lymphoproliferation and plasma cell dyscrasia are rare and
usually of independent clones [2]. The immunophenotyping
and light chain expression do not suggest a common evolution
from a lymphoplasmacytoid lymphoma. Our case is charac-
terized by clonal homology but discordant light chain expres-
sion, immunophenotype, and morphology. Plasma cell
myeloma with discordant light chain secretion is well docu-
mented [3]. Posttreatment switch in monoclonal protein may
also occur after SCT [4]. More dramatically, changes in
immunophenotype, morphology, and light chain expression
in B cell malignancies after rituximab treatment are also
recognized [1, 5, 6]. However, in our case, the clones occurred
concomitantly and upfront in distinct cell lineages. This may
theoretically result from plasma cell differentiation of the
malignant B lymphocytes or a divergent evolution from a
primordial B cell clone. Pools of malignant clonotypic B cells
are known to exist in PCM patients [7]. In terms of treatment,
W. Y. Au (*)
Department of Medicine, Queen Mary Hospital,
The University of Hong Kong,
UMU, 4/F, Professorial Block Pokfulam Road,
Pok Fu Lam, Hong Kong
e-mail: auwing@hotmail.com
L. Wai-Hung :K. Y. Wong :W. W. L. Choi
Department of Pathology, Queen Mary Hospital,
The University of Hong Kong,
Pok Fu Lam, Hong Kong
Ann Hematol
DOI 10.1007/s00277-012-1443-0
GH
I
E
D
F
A
C
B
MW          PC             NC             BM             TM       H20
242 bp
*
BM3
K
J
Ann Hematol
a combination of lymphoma and PCM treatment seems to be
effective in controlling both lesions with minimal overlap of
toxicity. It is uncertain whether this patient may have survival
benefit from an autologous SCT.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
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Fig. 1 a Computerized tomogram scan showing a gallbladder lesion
(arrow). b Positron emission tomogram scan showing FDG avid up-
take (arrows) in the porta hepatis as well as in the sternum, ribs, and
femur. c Magnetic resonance imaging showing osteolytic lesions in
multiple vertebra levels. d–f Marrow aspirate and trephine biopsy
showing heavy lymphoma infiltration with no evidence of plasma cell
dyscrasia. The B cells were highlighted by CD20 staining (f). g–i The
gallbladder lesion showed sheets of plasma cells with CD138 expres-
sion (g) negative for kappa light chain (h) but expressing lambda light
chain (i). j Polymerase chain reaction using IgH primers on DNA
extracted from marrow and gallbladder lesions showing bands of
similar band size (asterisk and arrow). MW molecular weight control,
PC positive control, NC negative control, BM bone marrow, TM tissue
material from gallbladder, H2O water blank. k Cloning, sequencing,
and alignment showing homology between clones from the two
discordant lesions
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